Dimensional Fund Advisors LP Purchases 108,001 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Dimensional Fund Advisors LP boosted its holdings in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 79.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 243,954 shares of the company's stock after purchasing an additional 108,001 shares during the period. Dimensional Fund Advisors LP owned approximately 0.48% of Sight Sciences worth $887,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. KCK LTD. bought a new stake in shares of Sight Sciences in the 4th quarter valued at about $15,925,000. Renaissance Technologies LLC increased its stake in Sight Sciences by 654.3% in the 4th quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock worth $1,431,000 after purchasing an additional 340,906 shares during the period. JPMorgan Chase & Co. lifted its position in Sight Sciences by 335.3% in the third quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company's stock valued at $439,000 after purchasing an additional 53,658 shares during the last quarter. Barclays PLC boosted its stake in shares of Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company's stock valued at $317,000 after purchasing an additional 38,248 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Sight Sciences in the fourth quarter worth approximately $96,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on SGHT. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Stifel Nicolaus cut their target price on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. UBS Group cut their target price on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Lake Street Capital increased their price objective on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday, May 9th. Finally, Piper Sandler cut their price objective on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $3.92.

Insider Buying and Selling at Sight Sciences

In related news, EVP Manohar K. Raheja bought 10,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the acquisition, the executive vice president now owns 145,000 shares of the company's stock, valued at $395,850. The trade was a 7.41% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 24,174 shares of the firm's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the transaction, the chief executive officer now owns 6,010,580 shares of the company's stock, valued at $13,824,334. The trade was a 0.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,196 shares of company stock valued at $81,001. 30.90% of the stock is currently owned by company insiders.

Sight Sciences Price Performance

SGHT stock opened at $3.24 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $8.45. The firm has a 50-day moving average of $2.81 and a 200 day moving average of $3.14. The company has a market cap of $167.50 million, a P/E ratio of -3.18 and a beta of 2.41.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. On average, sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.